Provided by Tiger Trade Technology Pte. Ltd.

HORIZON KINETICS MEDICAL ETF

35.29
+0.59351.71%
Post-market: 35.380.0865+0.25%16:00 EDT
Volume:148
Turnover:5K
Market Cap:16.59M
PE:- -
High:35.29
Open:35.23
Low:35.23
Close:34.70
52wk High:37.90
52wk Low:30.79
Shares:469.95K
Float Shares:469.95K
Volume Ratio:0.41
T/O Rate:0.03%
Dividend:0.41
Dividend Rate:1.16%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says

MT Newswires Live
·
Oct 02

Eli Lilly (LLY) Ends Cancer Development Deal with Foghorn Therapeutics

TIPRANKS
·
Oct 01

AbbVie Says Phase 3 Trials Show Rinvoq Vitiligo Repigmentation Gains Extend to Week 76

Reuters
·
Oct 01

Abbvie - Phase 3 Studies Show Continued Repigmentation with Rinvoq Through Week 76

THOMSON REUTERS
·
Oct 01

Abbvie - Rinvoq Plus NB-Uvb Shows Higher Repigmentation than Rinvoq Alone

THOMSON REUTERS
·
Oct 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)

TIPRANKS
·
Oct 01

AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data

GlobeNewswire
·
Oct 01

Veeva supporting transformation of medicine through AI, Barron’s reports

TIPRANKS
·
Oct 01

AbbVie to Host Third-Quarter 2026 Earnings Call Webcast

Reuters
·
Oct 01

Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials with Ely Lilly

Dow Jones
·
Oct 01

InflaRx Appoints Gabriela Alperovich as SVP, Global Head of Clinical Development

Reuters
·
Oct 01

Coty Names Kara Langan General Manager, U.S. Consumer Beauty Division

Reuters
·
Oct 01

Lilly Says Foundayo Cuts Predicted 10-Year Type 2 Diabetes Risk 57% in Attain-1 Post-Hoc Analysis

Reuters
·
Oct 01

Eli Lilly - Foundayo 17.2 Mg Associated with 57% Reduction in Diabetes Risk, 18% in Cardiovascular Risk Versus Placebo

Reuters
·
Oct 01

Eli Lilly - Foundayo Associated with Reduced Predicted Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease

THOMSON REUTERS
·
Oct 01

Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting

GlobeNewswire
·
Oct 01

Johnson & Johnson (JNJ) Stock Could Be Undervalued On Future Cash Flow

Simply Wall St.
·
Oct 01

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Dow Jones
·
Oct 01

Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial

Dow Jones
·
Oct 01

Eli Lilly’s Foundayo shows cardiovascular safety in type 2 diabetes study

TIPRANKS
·
Oct 01